After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved

[cafead]

via The devastations of the public markets and the repeated rejections handed down by the FDA have added up to a dim future for Zosano Pharma as it appears the 16-year-old biotech’s journey is coming to an end.

article source